Freund M, De Boben M, Diedrich H, Ganser A, Heil G, Heyll A, Henke M, Hiddemann W, Knauf U, Koch P
Dept. of Hematology/Oncology, Medical School, Hannover, FRG.
Haematol Blood Transfus. 1990;33:432-6. doi: 10.1007/978-3-642-74643-7_80.
Thirty-three patients with ALL/AUL in first relapse were treated with an induction of prednisone, vindesine, daunorubicin, Erwinia asparaginase, i.t. MTX (phase I), high-dose cytarabine, and etoposide (phase II). Twenty-one (64%) achieved a complete remission, one a partial remission. Side effects of induction-phase I were predominantly hematological with subsequent infections and gastrointestinal toxicity. In phase II some patients had additional cutaneous, ocular, and hepatic toxicity. The treatment efficiently induced remissions with tolerable toxicity in relapsed ALL. The disease-free survival, however, needs to be improved.
33例首次复发的急性淋巴细胞白血病/急性未分化白血病患者接受了泼尼松、长春地辛、柔红霉素、欧文氏菌天冬酰胺酶、鞘内甲氨蝶呤（I期）、大剂量阿糖胞苷和依托泊苷（II期）的诱导治疗。21例（64%）获得完全缓解，1例部分缓解。I期诱导治疗的副作用主要是血液学方面的，随后出现感染和胃肠道毒性。在II期，一些患者出现了额外的皮肤、眼部和肝脏毒性。该治疗能有效诱导复发的急性淋巴细胞白血病缓解，且毒性可耐受。然而，无病生存期仍需改善。
